Business
IDEAYA Announces Presentations at AACR Annual Meeting 2023 for Potential First-in-Class Synthetic Lethality Programs IDE397 (MAT2A), IDE161 (PARG) and Werner Helicase
SOUTH SAN FRANCISCO, Calif., March 14, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology
About this update from Ideaya Biosciences, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 14, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced publication of abstracts at the 2023 Annual Meeting of the American Association for Cancer Research (AACR). IDEAYA will present data for its potential first-in-class synthetic lethality programs IDE397, a Phase 1/2 methionine adenosyltransferase 2a (MAT2A) inhibitor, IDE161, a Phase 1/2 poly (ADP-ribose) glycohydrolase (PARG) inhibitor, and Werner Helicase, for which a development candidate is targeted in 2023. \n\n \n \n \n \n \n \n\n \nThe abstracts are available online at http://www.aacr.org in advance of the 2023 Annual Meeting of AACR, which will be held April 14-19, 2021. The posters will be available online at https://ir.ideayabio.com/events following the poster presentations. These data will be presented by IDEAYA in collaboration with Amgen (IDE397) and GSK (IDE397, Werner Helicase).\nAbstract 1644: \"Dual inhibition of MAT2A and PRMT5 delivers synergistic anti-tumor responses in preclinical models of MTAP-deleted cancer\" (Fischer, M. et al.)Date/Time: Monday April 17, 2023 at 9:00 am - 12:30 pm ETSession: Experimental and Molecular Therapeutics, Novel Antitumor Agents 4Location: Poster Section 18, Poster Board 1Presenters: IDEAYA, Amgen Abstract 1637: \"MAT2A inhibition in MTAP-/- tumors confers mechanistic vulnerabilities to multiple clinically actionable synthetic lethal drug combinations\" (Gerrick, K. et al.)Date/Time: Monday April 17, 2023 at 9:00 am – 12:30 pm ETSession: Experimental and Molecular Therapeutics, Novel Antitumor Agents 3Location: Poster Section 17, Poster Board 27Presenters: IDEAYA, GSK Abstract 6093: \"IDE161, a potential first-in-class clinical candidate PARG inhibitor, selectively targets Homologous-Recombination-Deficient and PARP inhibitor resistant breast and ovarian tumors\" (Abed, M. et al.)Date/Time: Wednesday April 19, 2023 at 9:00 am - 12:30 pm ETSession: Molecular/Cellular Biology and Genetics, Targeting DNA Damage Response and Novel PathwaysLocation: Poster Section 13, Poster Board 1Presenters: IDEAYA Abstract 1628: \"A small-molecule inhibitor of WRN selectively kills MSI-H cancer cells and phenocopies WRN genetic defects\" (Rao, Y. et al.)Da...